Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

University of Pennsylvania at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

University of Pennsylvania brings 40 presentations to ASH 2026 in New Orleans. Its program centres on cell therapy, myeloma and sickle cell disease. It covers armored CAR T cells for CD19-positive lymphoma and long-term blood toxicity after CAR T therapy.

OrganizationASH 2026 Attendance
Universities & research institutes
Private research university in Philadelphia, home to the Perelman School of Medicine.
Symposium
Fri Dec 11
7:00am–10:00am
B-Cell–Directed Therapies in Immune Thrombocytopenia: Real-World Practice
Newer B-cell-targeting treatments for immune thrombocytopenia and how to fit them into care to achieve lasting platelet responses.
Clotting · New drugs
Symposium
Fri Dec 11
3:00pm–6:00pm
Evidence at Every Step: Applying the Latest CAR T-Cell Data Across the NHL Care Continuum
Getting relapsed lymphoma patients to CAR-T sooner, with earlier referral, bridging therapy, sequencing choices, and management of immune and nerve toxicities.
Symposium hosted by PRIME Education
Lymphoma · Cell & gene
Symposium
Fri Dec 11
7:00pm–10:00pm
Addressing Community Oncologists’ Questions About BCMA-Directed Antibody-Drug Conjugates and Bispecific Antibodies in Multiple Myeloma – What Clinicians Want To Know
Answers to community oncologists' top questions on B-cell maturation antigen-targeted antibody-drug conjugates and bispecific antibodies in multiple myeloma.
Myeloma · New drugs
Talk
Sat Dec 12
2:00pm–3:15pm
Flt3 inhibitors in newly diagnosed and relapsed patients
Evidence behind current Flt3 inhibitor use in newly diagnosed and relapsed acute myeloid leukemia, and where investigational approaches are heading.
Leukemias · New drugs
Session
Sat Dec 12
4:00pm–5:35pm
JOINT SESSION - New Horizons in RNA Biology in Myeloid Development and Malignancy
How RNA regulation, from splicing to RNA-binding proteins, shapes healthy blood formation and myeloid cancers, and how it could point to new treatments.
Blood biology · Leukemias
Talk
Sun Dec 13
8:00am–9:00am
Talk
Sun Dec 13
4:30pm–5:45pm
Beyond Remission: Long-Term Hematopoietic Toxicity and Second Malignancies After CAR-T Cell Therapy
Persistently low blood counts and second cancers after CAR-T therapy, including their frequency, causes, and how to monitor, prevent, and manage them.
Cell & gene
Talk
Mon Dec 14
10:30am–11:45am
Indications and Timing of Splenectomy in Hereditary Hemolytic Anemia
When and how to remove the spleen in inherited red cell membrane and enzyme disorders, weighing benefit against lifelong infection and clotting risks.
Red cells
Talk
Mon Dec 14
4:30pm–6:00pm
Rational Design of FVIII Variants for Gene Therapy: Linking Molecular Insight to Therapeutic Performance
Engineering a better version of the clotting protein missing in hemophilia A for gene therapy, balancing stronger bleeding control against clot risk.
Clotting
Session
Tue Dec 15
11:30am–1:00pm

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at University of Pennsylvania

Tell us what you sell and we’ll find the people at University of Pennsylvania most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction